Executive Assistant
About the job
- At least 10 years of Executive Assistant or senior administrative support experience, preferably supporting senior leaders.
- Exceptional organizational, planning, and prioritization skills.
- Strong written and verbal communication skills.
- Ability to manage multiple priorities in a fast-paced environment.
- Advanced proficiency in Microsoft Office Suite.
- Ability to manage confidential and sensitive information with discretion.
- Provide high-level administrative support to the CHRO and CTOO.
- Manage complex calendars, schedules, and meeting logistics across multiple stakeholders and time zones.
- Coordinate domestic and international travel arrangements, itineraries, and expense reporting.
- Prepare meeting materials, presentations, agendas, and executive communications.
- Anticipate executive needs, proactively manage priorities, and ensure timely follow-up on key actions.
- Handle highly confidential information with professionalism and discretion.
- Support employee engagement and culture-building initiatives across the organization.
- Coordinate logistics and execution for Exchange Meetings, Anchor Weeks, employee recognition activities, leadership meetings, and company-wide events.
- Maintain HR-related communications, resources, and administrative processes.
- Coordinate vendor and contract administration activities for Human Resources and Technical Operations, including purchase order management, invoice processing, contract routing, and maintaining related documentation within company systems.
- Support department budget administration and vendor relationships.
- Partner closely with the Executive Administration team to ensure seamless support across the organization.
- Collaborate on company events, leadership meetings, and special projects.
- Participate in regular onsite activities in the Cambridge office, including team meetings, employee engagement events, onboarding activities, and other key business initiatives.
- Help foster a welcoming, professional, and collaborative workplace environment.
- Experience in biotechnology, pharmaceutical, healthcare, or other highly regulated industries.
- Experience with purchase order processing, invoice management, vendor administration, and systems such as LinkSquared, Workday, Concur, NetSuite, or similar business applications.
- Bachelor's degree or equivalent combination of education and experience.
About the company
Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, with a focus on ALS and Alzheimer's disease. Its main asset is AMX0035, currently in clinical trials, including the CENTAUR study for ALS and the PEGASUS study for late mild cognitive impairment or early dementia due to Alzheimer’s disease. The company advances products through rigorous, randomized, double-blind, placebo-controlled trials to demonstrate safety and efficacy before pursuing commercialization. In addition to research, Amylyx engages in awareness and community campaigns to support patients, caregivers, and researchers. The company aims to bring validated therapies to market to improve patient outcomes and generate revenue by selling treatments to healthcare providers and patients.
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2013
Get referred to Amylyx Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 18, 2026 LUCIDITY data showed a 55% hypoglycemia-event reduction.
- Amylyx raised $500 million in August 2026 to fund avexitide commercialization.
- Management plans an FDA NDA filing by year-end 2026 and a 2027 launch.
What critics are saying
- Avexitide failure leaves Amylyx without an approved product and crushes valuation.
- The 2024 Relyvrio withdrawal damaged credibility with regulators, physicians, and investors.
- A 2026 securities settlement for Relyvrio misstatements keeps litigation scars visible.
What makes Amylyx Pharmaceuticals unique
- Amylyx owns avexitide, a first-in-class GLP-1 antagonist for PBH.
- The FDA granted avexitide Breakthrough Therapy and Orphan Drug designations by 2026.
- Amylyx still retains ALS and rare-disease expertise after Relyvrio’s 2024 withdrawal.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Remote Work Options